• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Beta Bionics

The biggest diabetes tech stories out of ADA 2025

June 24, 2025 By Sean Whooley

ADA Logo in Chicago American Diabetes Association 85th Scientific Sessions

The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, ADA 2025, Beta Bionics, biolinq, Dexcom, Eli Lilly & Co., Glucotrack, Insulet, LifePlus, mannkind, Medtronic, minimed, modularmedical, PharmaSens, Senseonics, Sequel Med Tech, SiBionics, Tandem Diabetes Care, Vaxess Technologies

Analysts expect Beta Bionics patch pump launch by 2027

June 23, 2025 By Sean Whooley

Beta Bionics Logo (1)

BTIG analysts said today that Beta Bionics (Nasdaq:BBNX) expects to launch a new insulin patch pump system in the U.S. by the end of 2027. Marie Thibault, Sam Eiber and Alexandra Pang said the company revealed the new Mint system in a live demonstration at the American Diabetes Association’s 85th Scientific Sessions, outlining its plan […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: ADA 2025, Beta Bionics

Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

June 19, 2025 By Sean Whooley

Beta Bionics iLet bionic pancreas with Dexcom G7 and Abbott FreeStyle Libre 3 Plus

Beta Bionics (Nasdaq:BBNX) announced today that it agreed to integrate its iLet bionic pancreas with a future dual sensor from Abbott (NYSE:ABT). The agreement pairs the iLet automated insulin delivery system with the sensor designed to continuously monitor glucose and ketone levels. This marks the third such integration for the Abbott dual sensor. The company […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, Beta Bionics

Beta Bionics posts Q1 sales beat, raises 2025 guidance

May 6, 2025 By Sean Whooley

Beta Bionics Logo (1)

Beta Bionics (Nasdaq:BBNX) shares remained unmoved after hours today on first-quarter results that topped the consensus sales forecast. Following its first-quarter performance, Beta Bionics increased its full-year guidance. After previously projecting between $80 million and $85 million in revenue, it now expects between $82 million and $87 million. The Irvine, California-based automated insulin delivery technology developer […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: Beta Bionics

Doctors issue call to action to eliminate barriers to automated insulin delivery

April 9, 2025 By Sean Whooley

Diabetes automated insulin delivery AID platforms Insulet Medtronic Tandem Sequel Beta Bionics

Key opinion leaders issued a call to action to the diabetes community to recognize the importance of automated insulin delivery (AID). A number of doctors issued this call, published by Mary Ann Liebert’s Diabetes Technology & Therapeutics, to implement the advances made in the AID technology space. They say pivotal trials and real-world data support […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Beta Bionics, Diabetes, Insulet, Medtronic, Sequel Med Tech, Tandem Diabetes Care

Beta Bionics posts Q4 sales beat to cap off ‘momentum-building year’

March 25, 2025 By Sean Whooley

Beta Bionics iLet bionic pancreas with Dexcom G7 and Abbott FreeStyle Libre 3 Plus

Beta Bionics (Nasdaq:BBNX) shares rose after hours today on fourth-quarter results that topped the consensus sales forecast. Shares of BBNX ticked up nearly 2% to $15.50 apiece in poost-market trading today. This is the company’s first quarterly earnings report after it went public through a $234.6 million IPO in January. The Irvine, California-based automated insulin […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: Beta Bionics

Beta Bionics founder talks bringing ‘bionic pancreas’ to market

March 24, 2025 By Sean Whooley

Beta Bionics iLet Bionic Pancreas (2024)

Around 25 years ago, Ed Damiano’s 11-month-old son developed type 1 diabetes.  Damiano, a professor of mechanical engineering, made it his goal to make it easier to manage his young son’s condition.  Speaking on a panel at the MassMedic 2025 MedTech Symposium in Boston earlier this month, Damiano said: “I started to think about ways […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Beta Bionics

Beta Bionics goes public with upsized $234.6M IPO

January 30, 2025 By Sean Whooley

Beta Bionics Nasdaq Market

Beta Bionics (Nasdaq:BBNX) announced today that it went public after pricing a significantly upsized initial public offering (IPO). Earlier this month, the company filed a registration statement with the SEC relating to a proposed IPO. Beta Bionics, maker of the iLet bionic pancreas, later filed a prospectus outlining its aim to bring in $114.4 million in […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology, Wall Street Beat Tagged With: Beta Bionics

Beta Bionics to raise $114.4M in IPO

January 22, 2025 By Sean Whooley

Beta Bionics iLet Bionic Pancreas (2024)

Beta Bionics today filed a prospectus outlining its aim to bring in $114.4 million in its initial public offering (IPO). Earlier this month, the maker of the iLet bionic pancreas filed a registration statement with the SEC relating to a proposed IPO. Irvine, California-based Beta Bionics filed to list its common stock on the Nasdaq market […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Initial Public Offering (IPO), MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: Beta Bionics

Beta Bionics is proposing an IPO

January 7, 2025 By Sean Whooley

Beta Bionics iLet Bionic Pancreas (2024)

Beta Bionics announced today that it filed a registration statement with the SEC relating to a proposed initial public offering (IPO). The amount of shares of common stock included in the IPO and the price range remain undetermined. Irvine, California-based Beta Bionics filed to list its common stock on the Nasdaq market under the “BBNX” […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Technology, Wall Street Beat Tagged With: Beta Bionics

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS